Tag:
icatibant
Latest Headlines
Latest Headlines
Panel backs Shire's hereditary angioedema drug
In a 12 to one vote, an FDA panel backed Shire's Firazyr (icatibant) for acute attacks of hereditary angioedema (HAE) in patients 18 years and older. The panel also said patients should be able to
Jerini divests assets, focuses on icatibant
Jerini and Shire have reviewed Jerini's assets and have elected to divest Jerini Ophthalmic, JPT Peptide Technologies and Jerini's pre-clinical projects. Jerini will explore options to maximize
